Aspirin May Slow Decline in Mental Capacity Among Elderly Patients, Swedish Study Suggests

Source: ScienceDaily (10/22/12)

"In addition to preventing heart disease, acetylsalicylic acid has been shown to be effective against cancer according to several scientific studies. It is common practice in many countries to treat women at risk for heart disease with a small dose of acetylsalicylic acid."

A daily dose of acetylsalicylic acid equivalent to a fourth of an aspirin may slow the decline in intellectual capacity among elderly individuals with high cardiovascular risk. This is shown in a study by Sahlgrenska Academy, University of Gothenburg, Sweden.

Researchers at Sahlgrenska Academy, University of Gothenburg, over a five-year period studied how intellectual capacity changes among 681 elderly women (70 to 92 years) with heightened risk of suffering from a heart attack, vascular spasm or stroke.

Of the 681 women, 129 received a low daily dose of acetylsalicylic acid, equivalent to a fourth of an aspirin, to prevent heart disease. The Gothenburg study shows that acetylsalicylic acid also slowed decline in brain capacity among the elderly women. . .View Full Article

Biopharma Receives PDUFA Date for Lead Program
Source: Jason Kolbert (05/09/2025)

This is a critical milestone for the company and significant for the space given the lack of approved therapies, noted a D. Boral Capital report.

Biopharma Shares Efficacy Data at AUA Meeting
Source: Dr. Leland Gershell (05/01/2025)

These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report.

New Cell Treatment for Bladder Cancer Shows Promise
Source: Dr. Andres Maldonado (05/01/2025)

This investigative therapy is "uniquely positioned to occupy a distinct segment" within the evolving and crowded space, noted an H.C. Wainwright & Co. report.

Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial
Source: Streetwise Reports (04/29/2025)

Clinical-stage biopharmaceutical company Protara Therapeutics Inc. (TARA:NASDAQ) announces updated results from its trials of a drug for high-risk non-muscle invasive bladder cancer (NMIBC). Read why analysts are recommending this biopharmaceutical stock.

Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada
Source: Streetwise Reports (04/28/2025)

UroGen Pharma Ltd. (URGN:NASDAQ) unveiled nearly four years of durable response for JELMYTO in Nevada, offering a breakthrough for low-grade upper tract cancer patients. See how UroGen Pharmas breakthrough data could reshape non-surgical cancer treatments and drive future growth in the oncology sector.